Li Jin-Qi, Wang Jia-Feng, Li Jie, Zhang Shu-Han, He Dan, Tong Rong-Sheng, She Shu-Ya
Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital, Chengdu, China.
School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Biomed Chromatogr. 2018 Aug;32(8):e4252. doi: 10.1002/bmc.4252. Epub 2018 May 2.
The aim of this study was to develop an LC-MS/MS method for simultaneous determination of 20(S) protopanaxadiol (PPD) and its three metabolites, PPD-glucuronide (M1), (20S,24S)-epoxy-dammarane-3,12,25-triol (M2) and (20S,24R)-epoxydammarane-3,12,25-triol (M3), in rat plasma. Precipitation with acetonitrile was employed for sample preparation and chromatographic separations were achieved on a C column. The sample was detected using triple quadrupole tandem mass spectrometer with selected reaction monitoring mode. The monitored precursor-to-product ion transitions were m/z 459.4 → 375.3 for PPD, m/z 635.4 → 113.0 for M1, m/z 477.4 → 441.4 for M2 and M3 and m/z 475.4 → 391.3 for IS. The developed assay was validated according to the guidelines of the US Food and Drug Administration. The calibration curves showed good linearity over the tested concentration ranges (r > 0.9993), with the LLOQ being 1 ng/mL for all analytes. The intra- and inter-day precisions (RSD) were < 9.51% while the accuracy (RE) ranged from -8.91 to 12.84%. The extraction recovery was >80% and no obvious matrix effect was detected. The analytes were stable in rat plasma with the RE ranging from -12.34 to 9.77%. The validated assay has been successfully applied to the pharmacokinetic study of PPD as well as its metabolites in rat plasma. According to the pharmacokinetic parameters, the in vivo exposures of M1, M2 and M3 were 11.91, 47.95 and 22.62% of that of PPD, respectively.
本研究的目的是开发一种液相色谱-串联质谱法,用于同时测定大鼠血浆中20(S)-原人参二醇(PPD)及其三种代谢产物,即PPD-葡萄糖醛酸苷(M1)、(20S,24S)-环氧达玛烷-3,12,25-三醇(M2)和(20S,24R)-环氧达玛烷-3,12,25-三醇(M3)。采用乙腈沉淀法进行样品制备,并在C柱上实现色谱分离。使用三重四极杆串联质谱仪在选择反应监测模式下对样品进行检测。监测的前体离子到产物离子的跃迁为:PPD的m/z 459.4 → 375.3,M1的m/z 635.4 → 113.0,M2和M3的m/z 477.4 → 441.4,内标的m/z 475.4 → 391.3。所开发的分析方法按照美国食品药品监督管理局的指导原则进行了验证。校准曲线在测试浓度范围内显示出良好的线性(r > 0.9993),所有分析物的定量下限均为1 ng/mL。日内和日间精密度(RSD)均<9.51%,而准确度(RE)范围为-8.91%至1,2.84%。提取回收率>80%,未检测到明显的基质效应。分析物在大鼠血浆中稳定,RE范围为-12.34%至9.77%。经过验证的分析方法已成功应用于PPD及其代谢产物在大鼠血浆中的药代动力学研究。根据药代动力学参数,M1、M2和M3的体内暴露量分别为PPD的11.91%、47.95%和22.62%。